Efocipegtrutide (HM15211): Hanmi's GLP-1/GIP/Glucagon Triple Agonist Aims at Liver Disease, Not Just Weight (July 9, 2026)
Table of Contents
A triple agonist aimed at the liver, not the scale
The triple-agonist story is usually told through weight loss - retatrutide's headline-grabbing 24% to 28% reductions have made 'GLP-1/GIP/glucagon' shorthand for the most powerful obesity drugs in development. Efocipegtrutide, Hanmi Pharmaceutical's candidate known by the code HM15211, shares that exact three-receptor mechanism but was designed for a different target: the liver. Its lead indication is MASH (metabolic dysfunction-associated steatohepatitis, the condition formerly called NASH), the progressive form of fatty liver disease in which fat accumulation drives inflammation and scarring (fibrosis) that can end in cirrhosis. Hanmi has also pursued efocipegtrutide in cholestatic and fibrotic diseases - primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF) - where it holds orphan-drug designations. That MASH-first, fibrosis-focused positioning is what makes efocipegtrutide worth tracking as a distinct entry rather than another weight-loss contender.
Why add glucagon? The mechanistic case
GLP-1 and GIP are incretins - gut hormones that improve insulin secretion, slow gastric emptying, and reduce appetite. Glucagon is often thought of only as the hormone that raises blood sugar, which is why pairing it with insulin-promoting incretins seems counterintuitive. But glucagon does two things that matter for liver disease: it increases whole-body energy expenditure, and it acts directly on liver cells (hepatocytes) to stimulate the breakdown of stored fat. In a balanced triple agonist, the GLP-1 and GIP components counter glucagon's glucose-raising effect while its catabolic, fat-mobilizing action is put to work in the liver. Hanmi's preclinical data, presented at EASL and AASLD, go a step further: in chemically induced (TAA and CCl4) mouse models of liver injury, the anti-inflammatory and anti-fibrotic effects of efocipegtrutide depended on glucagon-receptor engagement. Remove the glucagon activity and the direct liver benefit faded. That is the crux of the triple-agonist thesis for MASH - the idea that a drug can improve the liver beyond what weight loss alone delivers.
The LAPSCovery design: making a peptide last a week
A peptide that hits three receptors is only useful if it survives long enough in the body to be dosed conveniently. Efocipegtrutide is a chemical conjugate: a chimeric tri-agonist peptide (TA15211) linked to a human immunoglobulin G4 (IgG4) Fc fragment through Hanmi's proprietary LAPSCovery ('Long-Acting Protein/Peptide Discovery') platform, yielding the molecule Hanmi calls a 'LAPSTriple Agonist.' The Fc fragment works as a molecular chaperone: it engages the neonatal Fc receptor (FcRn), the same recycling system that gives antibodies their long half-life, rescuing the drug from degradation and clearance. The result is a molecule that can be given once weekly by subcutaneous injection - the same convenience patients now expect from semaglutide and tirzepatide - while keeping all three receptor activities intact. This Fc-fusion approach is the same family of half-life-extension chemistry seen in once-weekly insulins and other next-generation metabolic peptides.
What the clinical data show so far
The most-cited human evidence comes from a Phase 1b/2a randomized, double-blind, placebo-controlled study in obese subjects with non-alcoholic fatty liver disease. Over 12 weeks, efocipegtrutide reduced liver fat content measured by MRI-PDFF in a clear dose-dependent fashion - roughly 19.6% at the lowest dose up to about 59.3% at the highest dose - compared with only about 5.7% on placebo, alongside reductions in body weight. Liver-fat reduction on imaging is an encouraging surrogate, but MASH approval ultimately turns on histology: whether a liver biopsy shows resolution of steatohepatitis and, ideally, improvement in fibrosis. That is what the current pivotal study, HM-TRIA-201 (NCT04505436), is built to measure - a Phase 2, adaptive, randomized, double-blind, placebo-controlled, multicenter, 52-week trial in patients with biopsy-confirmed MASH and fibrosis, run across the U.S. and Korea. A notable procedural milestone: the study's Independent Data Monitoring Committee (IDMC), which reviews unblinded safety and efficacy data, recommended the trial continue without modification - a reassuring sign that no safety or futility concerns forced a change.
How it compares - and where it fits
Efocipegtrutide is best understood alongside the other agents attacking fatty-liver disease through incretin biology. Retatrutide (Eli Lilly) is the other prominent GLP-1/GIP/glucagon triple agonist, but its center of gravity is obesity, with MASH as a secondary story. Survodutide (Boehringer Ingelheim) and pemvidutide (Altimmune) are GLP-1/glucagon dual agonists that lean explicitly into liver disease and have posted positive MASH data. Tirzepatide, the approved GLP-1/GIP dual agonist, improves MASH largely as a consequence of weight loss. Efocipegtrutide's differentiators are its MASH-first development strategy, its Fc-fusion long-acting design, its regulatory tailwinds (FDA Fast Track for MASH; FDA and EMA orphan designations for PBC, PSC, and IPF), and Hanmi's argument that the glucagon arm confers a direct anti-fibrotic effect. Whether that translates into biopsy-confirmed benefit that beats simpler agents is the open question.
What to watch, and the caveats
Efocipegtrutide is investigational: it is not approved anywhere, and its Phase 2 MASH data have not yet delivered the histologic endpoints that define success in this field. Much of the supporting evidence remains preclinical or early-phase, and some sits in conference posters rather than full peer-reviewed papers, so conclusions should be treated as preliminary. Like all incretin agonists it is expected to cause gastrointestinal side effects (nausea, vomiting, diarrhea), and the glucagon component adds specific questions about glucose and heart-rate effects that trials must resolve. Finally, a caution that applies to every compound we cover: efocipegtrutide is a proprietary Hanmi biologic - a peptide-Fc conjugate manufactured for regulated trials. Material sold online under the name 'efocipegtrutide' or 'HM15211' is not the clinical drug and cannot be assumed to be authentic, pure, or safe. The signal to watch over the next year is the HM-TRIA-201 histology readout - the moment that will tell us whether a glucagon-containing triple agonist can move fibrosis, not just liver fat.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Efocipegtrutide (HM15211) pipeline overview (Hanmi Pharmaceutical) Source
- [2] Study to Evaluate Efficacy, Safety and Tolerability of HM15211 - HM-TRIA-201 (ClinicalTrials.gov NCT04505436) Source
- [3] Hanmi Pharm's efocipegtrutide Phase 2 MASH trial gets green light from IDMC (Korea Biomedical Review) Source
- [4] Hanmi showcases efocipegtrutide's potential for liver fibrosis at AASLD (Korea Biomedical Review) Source
- [5] Next generation dual and triple GLP-1/GIP/glucagon agonists: a literature review (Nutr Metab Cardiovasc Dis) Source
Related Articles
A comprehensive guide to GLP-1 receptor agonists — how they work, what sets them apart, and where the science is heading.
CT-388: Roche's Signal-Biased Dual GLP-1/GIP Agonist Heads Into Phase 3 for Obesity (July 8, 2026)
Roche entered the obesity race late, but its Carmot-acquired dual GLP-1/GIP agonist CT-388 posted a placebo-adjusted 22.5% weight loss in Phase 2 and moved into Phase 3 in 2026. Here's what makes CT-388's 'signal-biased' mechanism distinct, what the QWINT-class data actually show, and how it stacks up against tirzepatide.